What the Research Says
Citicoline has one of the strongest evidence bases among nootropic compounds. McGlade et al. (2012) demonstrated cognitive improvements in healthy adults at just 250mg/day. The large body of stroke recovery literature, including the ICTUS trial, has led to its inclusion in medical guidelines across Europe and Japan. A 2021 systematic review confirmed benefits across multiple cognitive domains. The Cognizin branded form has been the subject of the majority of supplement-focused clinical trials, ensuring consistent quality and dosing.
